Patents by Inventor Masaki Ogino

Masaki Ogino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200392149
    Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: March 7, 2018
    Publication date: December 17, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi MIKAMI, Masaki DAINI, Yuhei MIYANOHANA, Hideo SUZUKI, Kenichiro SHIMOKAWA, Yuichi KAJITA, Masaki OGINO, Tatsuki KOIKE, Kohei TAKEUCHI
  • Publication number: 20200385346
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: December 10, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Masaki OGINO, Kohei TAKEUCHI, Tohru MIYAZAKI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • Publication number: 20200385345
    Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: March 7, 2018
    Publication date: December 10, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masaki DAINI, Yuhei MIYANOHANA, Satoshi MIKAMI, Yuichi KAJITA, Masaki OGINO, Tatsuki KOIKE, Kohei TAKEUCHI
  • Publication number: 20200231579
    Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 23, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Eiji KIMURA, Masaki OGINO, Yasuhisa KOHARA, Tomoko OHASHI, Tomohiro KAKU, Yuya OGURO, Shigemitsu MATSUMOTO, Takeshi WAKABAYASHI, Norihito TOKUNAGA, Taku KAMEI, Mitsuhiro ITO
  • Publication number: 20200227758
    Abstract: A positive electrode grid body for lead-acid battery includes frame rib including first and second lateral frame ribs and first and second longitudinal frame ribs, an inner rib including a plurality of lateral and longitudinal crosspieces, a plurality of opening portions, and a positive electrode current collection lug connected to the first lateral frame rib. In a region having a length of at least one opening portion or more in the lateral direction of the lateral crosspieces from the first longitudinal frame rib, a cross-sectional area of the plurality of lateral crosspieces located on at least the first lateral frame rib side becomes larger from the second longitudinal frame rib side toward a portion connected to the first longitudinal frame rib.
    Type: Application
    Filed: March 26, 2020
    Publication date: July 16, 2020
    Applicant: The Furukawa Battery Co., Ltd.
    Inventors: Yutaro KAWAGUCHI, Yusuke OGINO, Atsushi SATO, Shinya SUGE, Katsuya NUKUI, Akihiro NISHIMURA, Koshin TAKEMOTO, Ryo TAINAKA, Masashi MATSUSHITA, Hideki HAGIHARA, Masaki SHIMOTSUYA, Jun FURUKAWA
  • Publication number: 20200207734
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: July 2, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • Patent number: 10548877
    Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: February 4, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masaki Ogino, Eiji Kimura, Shinkichi Suzuki, Kouji Fuji, Tomohiro Ohashi, Makoto Fushimi, Kei Masuda, Tatsuki Koike, Takeshi Wakabayashi, Jinichi Yonemori, Masami Yamada
  • Patent number: 10548899
    Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: February 4, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masaki Ogino, Eiji Kimura, Masataka Murakami, Takuto Kojima, Jinichi Yonemori
  • Publication number: 20200017444
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: September 20, 2019
    Publication date: January 16, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • Publication number: 20190248776
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Application
    Filed: April 25, 2019
    Publication date: August 15, 2019
    Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Jinichi YONEMORI, Takuto KOJIMA
  • Publication number: 20190083467
    Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.
    Type: Application
    Filed: March 9, 2017
    Publication date: March 21, 2019
    Inventors: Masaki OGINO, Eiji KIMURA, Shinkichi SUZUKI, Kouji FUJI, Tomohiro OHASHI, Makoto FUSHIMI, Kei MASUDA, Tatsuki KOIKE, Takeshi WAKABAYASHI, Jinichi YONEMORI, Masami YAMADA
  • Patent number: 10214508
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: February 26, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masaki Ogino, Eiji Kimura, Shinkichi Suzuki, Tomoko Ashizawa, Toshihiro Imaeda, Ikuo Fujimori, Ryosuke Arai
  • Patent number: 10202376
    Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: February 12, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Eiji Kimura, Yuhei Miyanohana, Masaki Ogino, Yuta Tanaka, Makoto Fushimi, Tomohiro Okawa, Yuki Hanya, Tatsuki Koike
  • Publication number: 20190040010
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: February 7, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OHYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • Publication number: 20180303841
    Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.
    Type: Application
    Filed: October 19, 2016
    Publication date: October 25, 2018
    Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Takuto KOJIMA, Jinichi YONEMORI
  • Publication number: 20180162850
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Application
    Filed: June 23, 2016
    Publication date: June 14, 2018
    Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Jinichi YONEMORI, Takuto KOJIMA
  • Publication number: 20170362223
    Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.
    Type: Application
    Filed: December 21, 2015
    Publication date: December 21, 2017
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Eiji KIMURA, Yuhei MIYANOHANA, Masaki OGINO, Yuta TANAKA, Makoto FUSHIMI, Tomohiro OKAWA, Yuki HANYA, Tatsuki KOIKE
  • Publication number: 20170121308
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.
    Type: Application
    Filed: June 11, 2015
    Publication date: May 4, 2017
    Inventors: Masaki OGINO, Eiji KIMURA, Shinkichi SUZUKI, Tomoko ASHIZAWA, Toshihiro IMAEDA, Ikuo FUJIMORI, Ryosuke ARAI
  • Patent number: 9605000
    Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 28, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Masaki Ogino, Ryo Mizojiri, Takeshi Yamasaki, Hideki Hirose, Nobuyuki Takakura, Tohru Yamashita, Sachie Morimoto, Takashi Nakahata, Asato Kina
  • Publication number: 20160376244
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Application
    Filed: June 23, 2016
    Publication date: December 29, 2016
    Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Jinichi YONEMORI, Takuto KOJIMA